Patent · US Active

Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same

US11912829B2 · kind B2 · utility

0Cited by
4References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 1, 2021
Grant dateFeb 27, 2024
Priority date
Expiry dateNov 1, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC08L2205/05
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to a new class of cationic linear polyphosphazenes bearing as side groups a hydrophilic poly(ethylene glycol) and a spacer group selected from the group consisting of lysine, oligopeptides containing lysine, amino-ethanol, amino-propanol, amino-butanol, amino-pentanol and amino-hexanol, and the polyphosphazene-drug conjugates comprising hydrophobic anticancer drugs by covalent bonding and the preparation methods thereof. The present polyphosphazene-drug conjugates exhibit outstanding tumor selectivity and low toxicity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.